Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
6 clinical trials · Condition
◉ Watch Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma (NCT07023315) | Akeso | 2025-08-14 |
| Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer (NCT07026149) | Ruijin Hospital | 2025-06-08 |
| Pan-tumor MRD Study (NCT06605404) | Paradigm Health | 2025-01-08 |
| Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (NCT06693128) | Ruijin Hospital | 2024-11-21 |
| A Study of NDI 1150-101 in Patients With Solid Tumors (NCT05128487) | Nimbus Saturn, Inc. | 2021-11-05 |
| Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (NCT04208347) | Ruijin Hospital | 2019-12-18 |
Track Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.